Current opinion in hematology
-
To review the available clinical and biological advances of umbilical cord blood allogeneic stem cell transplantation in pediatric and adult patients. ⋯ Umbilical cord blood is a valuable alternative source of hematopoietic stem cells for patients that require allogeneic transplantation in the absence of readily available human leukocyte antigen matched marrow or blood hematopoietic stem cells. The current advances in clinical and biological research will further expand its application in pediatric and adult hematopoietic stem cells transplantation for treating hematologic disorders.
-
The present review summarizes the current therapies and controversies in the management of newly diagnosed and relapsed classical and lymphocyte predominant Hodgkin lymphoma and briefly describes novel agents in development for Hodgkin lymphoma. ⋯ Current trials employing risk-adapted therapy on the basis of interim fluoro-2-deoxy-D-glucose-positron emission tomography scans have the potential of improving outcomes for all patients with Hodgkin lymphoma, either by improving cure rates, minimizing toxicity, or both.
-
The discovery of a novel class of gene regulators, named microRNAs, has changed the landscape of human genetics. In hematopoiesis, recent work has improved our understanding of the role of microRNAs in hematopoietic differentiation and leukemogenesis. ⋯ There is now strong evidence that miRNAs modulate not only hematopoietic differentiation and proliferation but also activity of hematopoietic cells, in particular those related to immune function. Extensive miRNA deregulation has been observed in leukemias and lymphomas and mechanistic studies support a role for miRNAs in the pathogenesis of these disorders.